This is a drug monograph from the BSAVA Small Animal Formulary Part A: Canine and Feline. BSAVA members should login for access to the full monograph. Non-members can join BSAVA, buy a Formulary subscription, or buy the printed edition.
LondonCA ,HannahAL ,ZadovoskayaR et al. (2003)Phase I dose escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.Clinical Cancer Research9,2755–2768
LondonCA ,MalpasPB ,Wood-FollisSL et al.(2009)Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.Clinical Cancer Research15,3856–3865
Berger EP, Johannes CM and Post GS (2018) Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal of Feline Medicine and Surgery20, 95–102
Tjostheim SS, Stepien RL, Markovic LE and Stein TJ (2016) Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.Journal of Veterinary Internal Medicine30, 951–957
Frezoulis P and Harper A (2022) The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.Veterinary and Comparitive Oncology20, 362–371
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
